CA2440010C - Powder inhaler formulations - Google Patents

Powder inhaler formulations Download PDF

Info

Publication number
CA2440010C
CA2440010C CA2440010A CA2440010A CA2440010C CA 2440010 C CA2440010 C CA 2440010C CA 2440010 A CA2440010 A CA 2440010A CA 2440010 A CA2440010 A CA 2440010A CA 2440010 C CA2440010 C CA 2440010C
Authority
CA
Canada
Prior art keywords
powder
inhalation
component
sorbitan
mixing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2440010A
Other languages
English (en)
French (fr)
Other versions
CA2440010A1 (en
Inventor
Karoline Bechtold-Peters
Hanh Nguyen
Geoffrey Rowley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Publication of CA2440010A1 publication Critical patent/CA2440010A1/en
Application granted granted Critical
Publication of CA2440010C publication Critical patent/CA2440010C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2440010A 2001-03-21 2002-03-16 Powder inhaler formulations Expired - Fee Related CA2440010C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0107106.7A GB0107106D0 (en) 2001-03-21 2001-03-21 Powder inhaler formulations
GB0107106.7 2001-03-21
PCT/EP2002/002948 WO2002080884A2 (en) 2001-03-21 2002-03-16 Powder inhaler formulations

Publications (2)

Publication Number Publication Date
CA2440010A1 CA2440010A1 (en) 2002-10-17
CA2440010C true CA2440010C (en) 2012-07-10

Family

ID=9911273

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2440010A Expired - Fee Related CA2440010C (en) 2001-03-21 2002-03-16 Powder inhaler formulations

Country Status (10)

Country Link
US (3) US20030007932A1 (cg-RX-API-DMAC7.html)
EP (1) EP1372610B1 (cg-RX-API-DMAC7.html)
JP (1) JP2004523594A (cg-RX-API-DMAC7.html)
AT (1) ATE556704T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002316820A1 (cg-RX-API-DMAC7.html)
CA (1) CA2440010C (cg-RX-API-DMAC7.html)
GB (1) GB0107106D0 (cg-RX-API-DMAC7.html)
MX (1) MXPA03008398A (cg-RX-API-DMAC7.html)
UY (1) UY27218A1 (cg-RX-API-DMAC7.html)
WO (1) WO2002080884A2 (cg-RX-API-DMAC7.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CN102688224A (zh) * 2003-04-14 2012-09-26 维克特拉有限公司 用于提高剂量效率的药物组合物和装置
SE0302665D0 (sv) 2003-10-07 2003-10-07 Astrazeneca Ab Novel Process
ITMI20040795A1 (it) * 2004-04-23 2004-07-23 Eratech S R L Composizione farmaceutica solida secca suo processo di preparazione e sospensione acquosa stabile ottenuta dalla stessa
DE102004024451A1 (de) * 2004-05-14 2005-12-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierungen für die Inhalation, die Enantiomerenreine Betaagonisten enthalten
US9149433B2 (en) * 2004-11-30 2015-10-06 Basf Corporation Method for formation of micro-prilled polymers
BRPI0606364A2 (pt) 2005-02-10 2010-03-23 Glaxo Group Ltd processo para formar lactose adequada para uso em uma formulaÇço farmacÊutica
EP1917253B1 (de) 2005-08-15 2015-01-07 Boehringer Ingelheim International Gmbh Verfahren zur herstellung von betamimetika
EP1925295A1 (de) * 2006-11-22 2008-05-28 Boehringer Ingelheim Pharma GmbH & Co. KG Stabile Pulverformulierung enthaltend ein Anticholinergikum
CN101861311A (zh) 2007-07-21 2010-10-13 阿尔巴尼分子研究公司 5-吡啶酮取代的吲唑
CN103351390A (zh) 2007-11-21 2013-10-16 解码遗传Ehf公司 用于治疗肺部和心血管病症的联芳基pde4 抑制剂
CA2727055C (en) 2008-01-11 2016-12-20 Albany Molecular Research, Inc. (1-azinone) -substituted pyridoindoles as mch antagonists
EP2349224B1 (en) 2008-10-10 2017-05-10 Probelte Pharma, S.A. Orally administrable immunostimulant product for aquaculture
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
WO2010084499A2 (en) 2009-01-26 2010-07-29 Israel Institute For Biological Research Bicyclic heterocyclic spiro compounds
WO2010102065A1 (en) 2009-03-05 2010-09-10 Bend Research, Inc. Pharmaceutical compositions of dextran polymer derivatives
PT3130396T (pt) 2009-03-27 2021-05-12 Bend Res Inc Processo de secagem por pulverização
TR200909788A2 (tr) 2009-12-25 2011-07-21 Bi̇lgi̇ç Mahmut Tiotropyum içeren inhalasyona uygun kuru toz formülasyonu
US8834931B2 (en) 2009-12-25 2014-09-16 Mahmut Bilgic Dry powder formulation containing tiotropium for inhalation
WO2012031129A2 (en) 2010-09-03 2012-03-08 Bend Research, Inc. Spray-drying apparatus and methods of using the same
WO2012031133A2 (en) 2010-09-03 2012-03-08 Bench Research, Inc. Spray-drying apparatus and methods of using the same
US8815294B2 (en) 2010-09-03 2014-08-26 Bend Research, Inc. Pharmaceutical compositions of dextran polymer derivatives and a carrier material
US9248584B2 (en) 2010-09-24 2016-02-02 Bend Research, Inc. High-temperature spray drying process and apparatus
US9060938B2 (en) 2011-05-10 2015-06-23 Bend Research, Inc. Pharmaceutical compositions of active agents and cationic dextran polymer derivatives
US10105500B2 (en) 2012-05-09 2018-10-23 Virginia Commonwealth University Dry powder inhaler (DPI) designs for producing aerosols with high fine particle fractions
JP6233853B2 (ja) * 2012-05-14 2017-11-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 薬剤入りブリスタを収容する器具
US10105316B2 (en) 2012-07-05 2018-10-23 Arven llac Sanayi Ve Ticaret A.S. Inhalation compositions comprising muscarinic receptor antagonist
US10111957B2 (en) * 2012-07-05 2018-10-30 Arven Ilac Snayi ve Ticaret A.S. Inhalation compositions comprising glucose anhydrous
AU2015338717B2 (en) 2014-10-31 2018-12-20 Glaxosmithkline Intellectual Property Development Limited Powder formulation
CA2962719A1 (en) 2014-10-31 2016-05-06 Bend Research Inc. Process for forming active domains dispersed in a matrix
US11844859B2 (en) 2017-08-20 2023-12-19 Nasus Pharma Ltd. Dry powder compositions for intranasal delivery
CN110996912A (zh) * 2017-08-20 2020-04-10 福摩莱克斯医药创新有限公司 用于鼻内递送的干粉组合物
ES3038913T3 (en) 2018-03-20 2025-10-15 Icahn School Med Mount Sinai Beta-carboline derivatives as dyrk1a inhibitors for the treatment of e.g. diabetes
US11786460B2 (en) * 2018-04-16 2023-10-17 Ioulia Tseti Pharmaceutical dry powder composition for inhalation comprising a thyroid hormone
AU2019334202A1 (en) 2018-09-06 2021-03-25 Innopharmascreen, Inc. Methods and compositions for treatment of asthma or parkinson's disease
CA3124700A1 (en) 2018-12-31 2020-07-09 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
TW202541834A (zh) * 2024-04-16 2025-11-01 南韓商韓美藥品股份有限公司 吸入用組成物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL263733A (cg-RX-API-DMAC7.html) * 1960-04-19 1900-01-01
DE3013839A1 (de) * 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
US4533542A (en) * 1983-08-22 1985-08-06 Eli Lilly And Company Pharmaceutical compositions for storage in plastic containers and process therefor
GB9024366D0 (en) * 1990-11-09 1991-01-02 Glaxo Group Ltd Medicaments
GB9026025D0 (en) * 1990-11-29 1991-01-16 Boehringer Ingelheim Kg Inhalation device
US5354934A (en) * 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US6645644B1 (en) * 1996-10-17 2003-11-11 The Trustees Of Princeton University Enhanced bonding of phosphoric and phosphoric acids to oxidized substrates
US5874111A (en) * 1997-01-07 1999-02-23 Maitra; Amarnath Process for the preparation of highly monodispersed polymeric hydrophilic nanoparticles
DE69732306T2 (de) * 1997-01-16 2006-01-12 Massachusetts Institute Of Technology, Cambridge Zubereitung von partikelhaltigen arzneimitteln zur inhalation
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
ATE248583T1 (de) * 1997-09-29 2003-09-15 Nektar Therapeutics In dosierinhalatoren verwendbare, stabilisierte zubereitungen
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
CN1150895C (zh) * 1998-11-13 2004-05-26 杰格研究股份公司 用于吸入给药的干粉
EG23951A (en) * 1999-03-25 2008-01-29 Otsuka Pharma Co Ltd Cilostazol preparation

Also Published As

Publication number Publication date
EP1372610B1 (en) 2012-05-09
US20050196346A1 (en) 2005-09-08
WO2002080884A3 (en) 2003-10-16
JP2004523594A (ja) 2004-08-05
CA2440010A1 (en) 2002-10-17
US20030007932A1 (en) 2003-01-09
EP1372610A2 (en) 2004-01-02
UY27218A1 (es) 2002-10-31
AU2002316820A1 (en) 2002-10-21
ATE556704T1 (de) 2012-05-15
MXPA03008398A (es) 2004-01-29
US20080057003A1 (en) 2008-03-06
WO2002080884A2 (en) 2002-10-17
GB0107106D0 (en) 2001-05-09

Similar Documents

Publication Publication Date Title
EP1372610B1 (en) Powder inhaler formulations
EP1196146B1 (en) Powder particles with smooth surface for use in inhalation therapy
KR101763195B1 (ko) 건조 분말 반코마이신 조성물 및 관련 방법
HUP0004821A2 (hu) Lágy pellet alakjában lévő gyógyszerkészítmény és előállítása
AU2021200503B2 (en) Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation
CN1942172B (zh) 用于干粉吸入器的包含低剂量强力活性成分的药物剂型
EP2349204B1 (en) Inhalable particles comprising tiotropium
JP2009530416A (ja) 医薬組成物
AU2016356858A1 (en) A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
US20250387327A1 (en) Dry powder inhaler pharmaceutical composition of coated crystalline dry powder for inhalation
US20120101077A1 (en) Agglomerate formulations useful in dry powder inhalers
EP3030224B1 (en) Inhalable particles comprising tiotropium and indacaterol
KR100622625B1 (ko) 캐리어 입자 처리 방법 및 그 용도
CA2701956A1 (en) Combination therapy
EP1438960B2 (en) Compostion of itraconazole dispersed in a hydrophilic polymer having enhanced bioavailability
JPWO1999027911A1 (ja) 軟質ペレット状薬剤およびその製造方法
CZ20002053A3 (cs) Farmaceutický prostředek
HK1101346B (en) Pharmaceutical formulations for dry powder inhalers comprising a low-dosage strength active ingredient
JP2012524817A (ja) 標的粒子サイズを有する、活性医薬を含む凝集体配合物
JPWO2001056581A1 (ja) 吸入用粉末製剤及びそれを充填してなる粉末吸入剤

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20220301

MKLA Lapsed

Effective date: 20200831